AAV-Based Gene Therapy Products: Ongoing Clinical Trials

(June 2020)
We are happy to propose you an update on ongoing approved clinical trials on AAV-based gene therapy products.

The publication provides an accurate overview to explore the latest trials using AAV vectors for the treatment of: Cardiovascular Diseases, Hematological Diseases, Hepatic Diseases, Infectious Diseases, inherited Metabolic Diseases, Lysosomal Diseases, Neurological Diseases, Neuromuscular Diseases and Ophthalmological Diseases.

Diseases and trials mentioned have been put in context with the most relevant and recent publications and informations selected by our experts.

The trials presented here have been registered and/or updated on Clinicaltrials.gov until 04/30/2020.
GLOBAL CONTENT

■ Diseases mentioned P5
■ Products mentioned P6
■ Companies and Institutions mentioned P7
■ Highlights P8
■ Clinical trials using AAV-based Products by Numbers P10
  - Number of Trials by Therapeutic Area
  - Number of Products by Therapeutic Area
  - Number of Companies/Acad by Therapeutic Area
  - Number of Trials by Phase
  - Number of Products by Phase
  - Number of Companies/Acad by Phase
  - Number of Trials by Country

■ Ongoing Clinical Trials
  - Cardiovascular Diseases P16
  - Hematological Diseases P21
  - Hepatic Diseases P48
  - Infectious Diseases P51
  - Inherited Metabolic Diseases P52
  - Lysosomal Diseases P66
  - Neurological/Neurodegenerative Diseases P98
  - Neuromuscular Diseases P126
  - Ophthalmological Diseases P145
  - Miscellaneous P199
<table>
<thead>
<tr>
<th>DISEASES MENTIONED</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Critical Limb Ischemia (CLI)</td>
<td>P16</td>
</tr>
<tr>
<td>Refractory Angina</td>
<td>P18</td>
</tr>
<tr>
<td><strong>Hematological Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Hemophilia A</td>
<td>P22</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td>P33</td>
</tr>
<tr>
<td><strong>Hepatic Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Crigler Najjar Syndrome</td>
<td>P47</td>
</tr>
<tr>
<td><strong>Infectious Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>HIV-1 Infected Adults with Controlled Viremia</td>
<td>P50</td>
</tr>
<tr>
<td><strong>Inherited Metabolic Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>(excluding Lysosomal Diseases)</td>
<td></td>
</tr>
<tr>
<td>Glycogen Storage Disease IA</td>
<td>P52</td>
</tr>
<tr>
<td>Homozygous Familial</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>P55</td>
</tr>
<tr>
<td>Ornithine transcarbamylase deficiency</td>
<td>P58</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>P62</td>
</tr>
<tr>
<td><strong>Lysosomal Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Batten Disease</td>
<td>P66</td>
</tr>
<tr>
<td>Danon Disease</td>
<td>P68</td>
</tr>
<tr>
<td>Fabry Disease</td>
<td>P71</td>
</tr>
<tr>
<td>GM1 Gangliosidosis</td>
<td>P75</td>
</tr>
<tr>
<td>Mucopolysaccharidosis I</td>
<td>P79</td>
</tr>
<tr>
<td>Mucopolysaccharidosis II</td>
<td>P81</td>
</tr>
<tr>
<td>Mucopolysaccharidosis III</td>
<td>P83</td>
</tr>
<tr>
<td>Mucopolysaccharidosis VI</td>
<td>P89</td>
</tr>
<tr>
<td>Pompe Disease</td>
<td>P92</td>
</tr>
<tr>
<td><strong>Neurological/Neurodegenerative Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Disease</td>
<td>P98</td>
</tr>
<tr>
<td>Aromatic L-amino Acid DeCarboxylase Deficiency</td>
<td>P104</td>
</tr>
<tr>
<td>Charcot-Marie-Tooth Neuropathy</td>
<td>P108</td>
</tr>
<tr>
<td>Giant axonal neuropathy</td>
<td>P110</td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td>P114</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>P117</td>
</tr>
<tr>
<td><strong>Neuromuscular Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Duchenne Muscular Dystrophy</td>
<td>P126</td>
</tr>
<tr>
<td>Limb Girdle Muscular Dystrophy E</td>
<td>P133</td>
</tr>
<tr>
<td>Spinal muscular atrophy</td>
<td>P135</td>
</tr>
<tr>
<td>X-linked myotubular myopathy</td>
<td>P141</td>
</tr>
<tr>
<td><strong>Ophthalmological Diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Achromatopsia</td>
<td>P147</td>
</tr>
<tr>
<td>Age-related Macular Degeneration</td>
<td>P154</td>
</tr>
<tr>
<td>Choroideremia</td>
<td>P163</td>
</tr>
<tr>
<td>Leber Congenital Amaurosis</td>
<td>P169</td>
</tr>
<tr>
<td>Leber Hereditary Optic Neuropathy</td>
<td>P177</td>
</tr>
<tr>
<td>Retinitis pigmentosa</td>
<td>P185</td>
</tr>
<tr>
<td>X-linked retinitis pigmentosa</td>
<td>P192</td>
</tr>
<tr>
<td>X-linked juvenile retinoschisis</td>
<td>P197</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
</tr>
<tr>
<td>Ageing</td>
<td>P199</td>
</tr>
<tr>
<td>Irradiation-Induced Parotid Salivary</td>
<td></td>
</tr>
<tr>
<td>Hypofunction/Radiation-induced Xerostomia</td>
<td>P201</td>
</tr>
<tr>
<td>Osteoarthritis of the Knee</td>
<td>P203</td>
</tr>
</tbody>
</table>
Two AAV-based gene therapy products have already obtained the go-ahead from US and European health authorities:

**Luxturna®** received [FDA approval](https://www.fda.gov) in December 2017 as a one-time gene therapy to restore functional vision in children and adult patients with biallelic mutations of the RPE65 gene (Leber congenital amaurosis, retinitis pigmentosa). The European Commission approved **Luxturna®** in December 2018. This gene therapy was developed by Children’s Hospital of Philadelphia and Spark Therapeutics, now a Roche company.

**Zolgensma®** has been approved by the [FDA](https://www.fda.gov) in May 2019 for the treatment of pediatric patients less than 2 years of age with SMA type I with bi-allelic mutations in the SMN1 gene. This gene therapy has been approved in the [EU](https://www.europa.eu) in May 2020. This gene therapy was developed by Avexis, now a Novartis company.

116 clinical trials using AAV-based gene products are currently ongoing

These 116 clinical trials involve 81 products for the treatment of 40 diseases.

Ophthalmological diseases and lysosomal diseases are the most represented therapeutic areas.

![NUMBER OF COMPANIES/ACAD BY THERAPEUTIC AREA](image)
Examples of Ongoing Clinical Trials Presented in the Study
Hematological Diseases

Hemophilia

Hemophilia is an X-linked genetic disease in which blood doesn’t clot properly. Hemophilia A is a deficiency of coagulation factor VIII (FVIII) and Hemophilia B is a deficiency of coagulation factor IX (FIX).

Latest Publications on the Disease

- “A Molecular Revolution in the Treatment of Hemophilia”. Butterfield JSS et al. Department of Pediatrics, University of Florida, Gainesville, FL, USA.

Diverse molecular medicines, ranging from antibody to gene to RNA therapy, are transforming treatment of monogenetic bleeding disorders hemophilia A and B. The article provides an overview of these approaches, explains how they differ from standard therapies, and predicts how the hemophilia treatment landscape will be reshaped.


This review describes the preclinical and phase 1/2 studies investigating innovative products, including factor concentrates and non-clotting factor-based therapies with extended half-life, for the management of hemophilia patients with or without coagulation factor inhibitors. Among replacement therapies for hemophilia A, these results indicate that the most interesting products are those bioengineered using XTEN fusion technology. The anti-tissue factor pathway inhibitor antibody concizumab is the most innovative and interesting agent among non-clotting factor products.

*Expert Opin Investig Drugs*. 2020 Feb 3:1-7. ([Abstract])

- Gene therapy for hemophilia”. Nathwani AC. Department of Haematology, UCL Cancer Institute, Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, UK; and Freeline Therapeutics.

Hemophiliacs are ideally suited for gene therapy because a small increment in blood factor levels (≥5% of normal) is associated with significant amelioration of bleeding phenotype in severely affected patients. This review explores recent progress and the remaining limitations that need to be overcome for wider availability of this novel treatment of inherited bleeding disorders.


SB-525 is an AAV2/6 vector encoding the cDNA for the B-domain deleted human Factor VIII (FVIII) for the treatment of hemophilia A. The secreted FVIII has the same amino acid sequence as approved recombinant anti hemophilic factors (Refacto® and Xyntha®). The SB-525 vector encodes a liver-specific promotor module and AAV2/6 exhibits liver tropism, thus providing the potential for long-term hepatic production of FVIII in hemophilia A subjects.

SB-525 is developed by Sangamo Therapeutics in collaboration with Pfizer since May 2017. Sangamo led Phase 1/2 clinical trials. In December 2019, the biotech company has completed the transfer to Pfizer of the SB-525 Investigational New Drug application (IND). Pfizer is now advancing SB-525 into a Phase 3 registrational clinical study in 2020 and has already commenced enrolling patients into a Phase 3 lead-in study.

The FDA has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to SB-525, which also received Orphan Medicinal Product designation from the EMA.

Latest Informations/Publications on the Product

**JULY 2019**

Sangamo and Pfizer announce updated Phase 1/2 results for SB-525 showing sustained increased Factor VIII levels. The Phase 1/2 Alta study has been designed to assess the safety and tolerability of SB-525 in ten male patients with severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in FVIII activity levels. The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII activity as measured using a chromogenic assay, with no reported bleeding events. The response continues to be durable for as long as 24 weeks, the extent of follow-up. The two patients more recently treated at the 3e13 vg/kg dose level are demonstrating FVIII activity kinetics that appear consistent with the first two patients treated in this dose cohort at similar early time points. Across the dose cohorts, patients demonstrated a dose-dependent increase in FVIII levels and a dose-dependent reduction in the use of FVIII replacement therapy. ([Press Release](#))
Ongoing Clinical Trials

*Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FIX:C≤1%)*

The study is an open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of current factor IX (FIX) or factor VIII (FVIII) prophylaxis replacement therapy in the usual care setting of moderately severe to severe adult hemophilia b subjects (FIX:c≤2%) who are negative for neutralizing antibodies to adeno-associated virus vector-Spark100 (benegene-1) and moderately severe to severe hemophilia a adult subjects (FVIII:c≤1%) who are negative for neutralizing antibodies to adeno-associated virus vector SB-525 capsid (aav6), prior to the respective therapeutic phase 3 gene therapy studies.

**PHASE 3**

**ID:** NCT03587116  
**Recruitment Status:** Recruiting  
**Start/Planned completion:** JUL 2018/OCT 2021  
**Estimated Enrollment:** 250  
**Sites:** 64 (AU, AT, BE, BR, CA, DE, ES, FR, GR, IL, IT, JP, KR, SA, SW, TK, TW, UK)  
**Updated:** February 28, 2020  
**Contact:** Pfizer CT.gov Call Center - 1-800-718-1021 - ClinicalTrials.gov_Inquiries@pfizer.com

**Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A**

The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity levels with adaptive doses of SB-525. The objective of the study is to reduce or eliminate the need for FVIII replacement therapy.

**PHASE 2**

**ID:** NCT03061201  
**Recruitment Status:** Recruiting  
**Start/Planned completion:** JUN 2017/JUL 2024  
**Estimated Enrollment:** 13  
**Sites:** 8 (USA)  
**Updated:** February 27, 2020  
**Contact:** Pfizer CT.gov Call Center - 1-800-718-1021 - ClinicalTrials.gov_Inquiries@pfizer.com
Valoctocogene Roxaparvovec (BMN 270) is an investigational AAV5 containing a B-domain deleted variant of FVIII gene. In February 2020, the FDA has accepted for Priority Review the Biologics License Application (BLA) for valoctocogene roxaparvovec, for the treatment of adults with hemophilia A. The agency has granted priority review designation to valoctocogene roxaparvovec and the Prescription Drug User Fee Act (PDUFA) action date is August 21, 2020. The FDA has already granted valoctocogene roxaparvovec Breakthrough Therapy designation and Orphan Drug designation.

The EMA also validated BioMarin’s Marketing Authorization Application (MAA) for valoctocogene roxaparvovec, for adults with severe hemophilia A. The MAA review commenced in January 2020 under accelerated assessment. Valoctocogene roxaparvovec has Orphan Drug designation from the EMA that also granted access to its Priority Medicines (PRIME) regulatory initiative in 2017.

This submission marks the first marketing application under review in Europe for a gene therapy product for any type of hemophilia. If approved by the FDA, valoctocogene roxaparvovec will be the first gene therapy in the US for the treatment of any hemophilia.

Ongoing Clinical Trials

Gene Therapy Study in Severe Haemophilia A Patients – A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A

**PHASE 1-2**
**ID:** NCT02576795
**Recruitment Status:** Active, not recruiting
**Start/Planned completion:** AUG 2015/FEB 2022
**Estimated Enrollment:** 15
**Sites:** 9 (UK)
**Updated:** April 17, 2019
**Contact:** -

This study is being conducted by Biomarin Pharmaceutical as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy vector in participants with severe Haemophilia A.)
This article demonstrated that a single infusion of valoctocogene roxaparvovec resulted in sustained, clinically relevant benefit, as measured by a substantial reduction in annualized rates of bleeding events and complete cessation of prophylactic factor VIII use in all 13 participants who had received 4e13vg/kg or 6e13 vg/kg.

Twelve of these participants also experienced a full resolution of target joints. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).


**Gene Therapy Study in Severe Haemophilia A Patients With Antibodies Against AAV5 (270-203)**

**PHASE 1-2**

**ID:** [NCT03520712](https://clinicaltrials.gov/ct2/show/NCT03520712)

**Recruitment Status:** Enrolling by invitation

**Start/Planned completion:** APR 2018/JUN 2024

**Estimated Enrollment:** 10

**Sites:** 2 (UK)

**Updated:** April 8, 2019

**Contact:** -

This study is being conducted as an open label, single dose study in order to determine the safety of valoctocogene roxaparvovec in participants with severe hemophilia A who also have pre-existing antibodies against AAV5.
Fidanacogene elaparvovec (PF-06838435 - SPK-9001) is an AAV-based gene therapy that contains a high-activity human coagulation factor IX gene. The product received orphan drug designation from the FDA in September 2015 and breakthrough therapy designation in July 2016. It has been granted support through the European Medicines Agency (EMA) PRIority MEdicines (PRIME) program in February 2017. ODD status has been granted in the EU in November 2018.

Ongoing Clinical Trials

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

PHASE 3
ID: NCT03861273 - BENEGENE-2
Recruitment Status: Recruiting
Start/Planned completion: JUL 2019/NOV 2026
Estimated Enrollment: 55
Sites: 31 (AU, CA, GR, JP, SA, TK, TW, UK, USA)
Updated: April 10, 2020
Contact: Pfizer CT.gov Call Center - 1-800-718-1021 - ClinicalTrials.gov_Inquiries@pfizer.com

This study will evaluate the efficacy and safety of PF-06838435 in adult male participants with moderately severe to severe hemophilia B (Factor IX circulating activity of 2% or less). Eligible study participants will have completed a minimum 6 months of routine Factor IX prophylaxis therapy during the lead in study (C0371004). Participants will be dosed once and will be evaluated over the course of 6 years. The main objectives of the study are to compare the annualized bleeding rate of the gene therapy to routine prophylaxis from the lead-in study and to evaluate the impact that it may have on participant’s Factor IX circulating activity.
The study is a long term follow up (LTFU) study designed to evaluate the overall long term safety, durability of transgene expression, and effect on clinical outcomes of SPK 9001 mediated gene transfer. While safety will be monitored in general, new onset of oncologic, hematologic, neurologic, or autoimmune events will be of particular interest. This trial will last for 5 years providing a minimum of 6 years of follow up post vector administration.
Danon Disease

Danon disease is a rare X-linked genetic disorder characterized by cardiomyopathy, skeletal muscles myopathy and intellectual disability. This lysosomal-associated disorder is leading to early death due to heart failure. Danon disease is caused by mutations in the LAMP2 gene that provides instructions for making lysosomal associated membrane protein-2 (LAMP-2). The absence or reduction of LAMP2 protein leads to disruption of intracytoplasmic trafficking with an accumulation of autophagic material and glycogen in cardiac muscle and skeletal muscle cells.

There are no therapies available for the treatment of Danon disease.

Latest Publications on the Disease

- « Danon Disease ». Matthew RG Taylor. Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Eric D Adler, Division of Cardiology, University of California San Diego, San Diego, California, USA. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020. 2020 Mar 5. (Abstract - Full Text)

- « Lysosomal Abnormalities in Cardiovascular Disease ». Congwu Chi et al. Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. In this review, the authors highlighted studies that have improved our understanding of the connection between lysosome function and cardiovascular diseases with an emphasis on a recent breakthrough that characterized a unique autophagosome-lysosome fusion mechanism employed by cardiomyocytes through a lysosomal membrane protein LAMP-2B. This finding may impact the development of future therapeutic applications. Int J Mol Sci. 2020 Jan 27;21(3):811. (Abstract - Full Text)

- « Danon Disease: Review of Natural History and Recent Advances ». G Cenacchi et al. Department of Biomedical and Neuromotor Sciences, “Alma Mater” University of Bologna, Bologna, Italy. The authors surveyed over 500 Danon disease patients reported in the literature from the first description to the present, in order to summarize the clinical, pathological and molecular data and treatment perspectives. Neuropathol Appl Neurobiol. 2019 Nov 7. (Abstract)
RP-A501 (AAV9.LAMP2B) is a recombinant AAV9 containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene. The LAMP2 gene, a key mediator of autophagy, has three isoforms: LAMP2A, LAMP2B, and LAMP2C. LAMP2B is the predominant isoform expressed in cardiomyocytes. In February 2019 Rocket Pharmaceuticals was notified by the FDA that the company was granted Fast Track designation for RP-A501.

Latest Informations/Publications on the Product

- « Systemic AAV9.LAMP2B Injection Reverses Metabolic and Physiologic Multiorgan Dysfunction in a Murine Model of Danon Disease ». Ana Maria Manso, Division of Cardiology, Department of Medicine, UC San Diego, San Diego, CA 92037, USA.

This study evaluates the efficacy of human LAMP2B gene transfer using a recombinant adeno-associated virus 9 carrying human LAMP2B (AAV9.LAMP2B) in a Lamp2 knockout (KO) mouse, a Danon disease model. AAV9.LAMP2B was intravenously injected into 2- and 6-month-old Lamp2 KO male mice to assess efficacy in adolescent and adult phenotypes. Lamp2 KO mice receiving AAV9.LAMP2B demonstrated dose-dependent restoration of human LAMP2B protein in the heart, liver, and skeletal muscle tissue. Impaired autophagic flux, evidenced by increased LC3-II, was abrogated by LAMP2B gene transfer in all tissues in both cohorts. Cardiac function was also improved, and transaminases were reduced in AAV9.LAMP2B-treated KO mice, indicating favorable effects on the heart and liver. Survival was also higher in the older cohort receiving high vector doses. In summary, LAMP2B gene transfer improves metabolic and physiologic function in a DD murine model, suggesting that a similar therapeutic approach may be effective for treating patients with this highly morbid disease.


- MAY 2019
Rocket Pharmaceuticals has presented preclinical data of RP-A501 at the American Society of Gene and Cell Therapy 2019 Annual Meeting in Washington, D.C. IND-enabling toxicology studies were conducted in wild-type mice and non-human primates. Three dose levels were tested in mice, including 3×10^{13} vg/kg, 1×10^{14} vg/kg, and 3×10^{14} vg/kg. The highest dose level from the murine study, 3×10^10 vg/kg, was tested in non-human primates. No dose-Latest adverse events were observed at all tested doses in both mice and non-human primates. Vector genomes, mRNA and protein expression were widely distributed across key tissues with high levels of transduction, transcription and translation detected in the heart, skeletal muscle, diaphragm and liver. (Press Release)
Ongoing Clinical Trials

Gene Therapy for Male Patients With Danon Disease Using RP-A501; AAV9.LAMP2B

This non-randomized open-label Phase 1 study evaluates the safety and toxicity of gene therapy using a recombinant AAV9 containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD). RP-A501 will be administered as a single IV infusion. Two dose levels are planned to be investigated in 4 distinct cohorts:

- **Cohort 1**: Age 15 years and older: Low Dose (n=3-6 subjects);
- **Cohort 2**: Age 15 years and older: High Dose (n=3-6 subjects);
- **Cohort 3**: Age 8-14 years: Low Dose (n=3-6 subjects);
- **Cohort 4**: Age 8-14 years: High Dose (n=3-6 subjects).

Clinical data read-outs are expected in the second half of 2020.

Latest Informations/Publications on Clinical Trials

**JUN 2019**
« Rocket Pharmaceuticals Announces Patient Dosing Has Commenced for Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome »

Patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501 for the treatment of Danon disease. University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler M.D. and Barry Greenberg M.D.

Eric Adler is Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California, San Diego School of Medicine.

Barry Greenberg, is the Director of the Advanced Heart Failure Treatment Program at UCSD Health and Professor of Medicine at UC San Diego School of Medicine, and is principal investigator of the trial. ([Press Release])
Vectors based on AAV have shown the ability for gene delivery to retinal organoids derived from hiPSCs. Thus far, little work has been carried out to investigate mechanisms of AAV-mediated gene delivery and the potential advantages of engineered AAVs to genetically modify retinal organoids. In this study, the authors compared the early transduction efficiency of several recombinant and engineered AAVs in hiPSC-derived RPE cells and retinal organoids in relation to the availability of their cell-surface receptors and as a function of time. The genetic variant AAV2-7m8 had a superior transduction efficiency when applied at day 44 of differentiation on retinal organoids and provided long-lasting expressions for at least 4 weeks after infection without compromising cell viability. All of the capsids tested transduced the hiPSC-RPE cells, with the AAV2-7m8 variant being the most efficient. Transduction efficiency was correlated with the presence of primary cell-surface receptors on the hiPS-derived organoids.

Int J Mol Sci. 2020 Feb; 21(3): 994. (Full Text)
Achromatopsia is a rare autosomal recessive inherited retinal disease (IRD) characterized by a partial or total absence of color vision. It prevents cone photoreceptors from functioning. Affected people can also have an increased sensitivity to light and glare, involuntary back-and-forth eye movements, and significantly reduced sharpness of vision. They can also have farsightedness or, less commonly, nearsightedness.

The disease results from mutations in one of several genes (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, ATF6). These mutations affect cone photoreceptors which are the specialist light-sensing cells responsible for colour vision and vision in bright light. The CNGB3 and CNGA3 genes are the two most common genes that have been identified as causing achromatopsia.

AAV-CNGA3 (AAV2/8-hG1.7p.coCNGA3) is an AAV-based gene therapy designed to restore cone function in patients with achromatopsia (ACHM) caused by mutations in the Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene. This AAV 2/8 is carrying a proprietary engineered promoter (hG1.7p) driving a codon-optimized CNGA3 cDNA. The product is delivered via subretinal injection covering the central macula region of the eye, where most of the cones in the retina are located.

AAV-CNGA3 was granted orphan drug designation by the FDA and by the European Medicines Agency in August 2018. In January 2019, MeiraGTx has established collaboration and license agreement with Janssen with respect to three MeiraGTx’s IRD pipeline, including AAV-CNGA3.

**Latest Informations/Publications on the Product**

- **APR 2019**
  « MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019 »

A pre-clinical poster on safety and efficacy of AAV-CNGA3 has been presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, British Columbia. In pre-clinical models, treatment with AAV-CNGA3 resulted in long-term visual improvements and cone photoreceptor survival at titers planned for use in a Phase 1/2 clinical trial of AAV-CNGA3. (Press Release)
Ongoing Clinical Trials

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

This study is a longer-term follow-up study for patients who participated in one of the clinical trials: AAV - CNGB3 retinal gene therapy for patients with achromatopsia, or AAV - CNGA3 retinal gene therapy for patients with achromatopsia.

Gene Therapy for Achromatopsia (CNGA3) (CNGA3)

This study is recruiting patients with achromatopsia for a follow-up study.

**PHASE 1-2**

**ID:** NCT03278873  
**Recruitment Status:** Recruiting  
**Start/Planned completion:** JUN 2017/AUG 2024  
**Estimated Enrollment:** 72  
**Sites:** 1 (UK)  
**Updated:** September 12, 2019  
**Contact:**  
MeiraGTx UK II Ltd +44 (0)20 3866 4320 - ocularinfo@meiragtx.com

**PHASE 1-2**

**ID:** NCT03758404  
**Recruitment Status:** Recruiting  
**Start/Planned completion:** JUL 2019/JAN 2022  
**Estimated Enrollment:** 18  
**Sites:** 2 (UK, USA)  
**Updated:** March 12, 2020  
**Contact:**  
MeiraGTx UK II Ltd +44 (0)20 3866 4320 - ocularinfo@meiragtx.com
AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) is an AAV-based gene therapy designed to restore cone function in patients with achromatopsia (ACHM) caused by mutations in the Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene.

Latest Informations/Publications on the Product

**MAR 2020**

« AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia »

The planned enrollment has been completed in all dose groups for adult patients, including the two higher dose groups, of the Phase 1/2 clinical programs with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. AGTC continues to enroll pediatric patients at the higher dose groups in both trials. AGTC most recently reported interim six-month data from the dose escalation cohorts of its ongoing ACHM Phase 1/2 clinical trials in January 2020. Results from both studies demonstrated encouraging signs of biologic activity as shown by positive changes in light discomfort testing as well as encouraging patient anecdotes describing real-world improvements in visual function. A favorable safety profile with no dose-limiting inflammatory responses was observed. ([Press Release](#))

« Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia Sheep »

Gootwine E et al. Agricultural Research Organization, The Volcani Center, Rishon LeZion, Israel

The results are herein reported of a study evaluating safety and efficacy of AGTC-402 in CNGA3-deficient sheep. Thirteen day-blind sheep divided into three groups of four or five animals each received a subretinal injection of an AAV vector expressing a CNGA3 gene in a volume of 500 μL in the right eye. Two groups (n = 9) received either a lower or higher dose of the AGTC-402 vector, and one efficacy control group (n = 4) received a vector similar in design to one previously shown to rescue cone photo-receptor responses in the day-blind sheep model (rAAV5-PR2.1-hCNGA3). All vector-treated eyes showed improved cone-mediated electroretinography responses with no change in rod-mediated electroretinography responses. Behavioral maze testing under photopic conditions showed significantly improved navigation times and reduced numbers of obstacle collisions in all vector-treated eyes compared to their contralateral control eyes or pre-dose results in the treated eyes.

Ongoing Clinical Trials

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia

PHASE 1-2
ID: [NCT02935517](#)
Recruitment Status: Recruiting
Start/Planned completion: MAY 2017/JUN 2023
Estimated Enrollment: 24
Sites: 9 (IL, USA)
Updated: January 14, 2020
Contact: Jill Dolgin, PharmD + 1833-770-2862 - advocacy@agtc.com

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy. Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be at least 18 years of age and will receive a lower, middle or higher dose of study agent. Subjects in Group 4 will be at least 6 years of age and will receive the maximum tolerated dose identified in Groups 1, 2 and 3. Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology and clinical chemistry parameters. Efficacy parameters will include visual acuity, light discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging and OCT.

Latest Informations/Publications on Clinical Trials

- JAN 2020
  « AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia »

Interim results from the ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGA3 gene demonstrate encouraging signs of biologic activity and a favorable safety profile. The company plans to report data from additional dose groups, age groups and time-points in the second half of 2020. The data reported are from 9 patients in the ACHM CNGA3 trial. Additional data are expected to be available in the second half of 2020. ([Press Release](#))